Revolution Medicines Highlights NEJM Publication Of RASONQUE Lung Cancer Data

Revolution Medicines (RVMD) said NEJM published Phase 1/2 data on RASONQUE (daraxonrasib), its oral RAS(ON) multi-selective inhibitor, in previously treated patients with advanced RAS-mutant cancer. The news is a positive scientific validation step, though the excerpt provides no efficacy/safety numbers to gauge magnitude. Overall impact is likely modest for the stock near term.